logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Why VTV Therapeutics' stock added over 48% to its price before trading hours today

VTV Therapeutics’ (VTVT) stock price added over 48% before trading hours today. The news that some believe is behind investors’ enthusiasm is the firm’s announcement that it will deliver two presentations at the 11 th clinical trials on Alzheimer’s Disease...

Read More

October 17, 2018

0

Why Portola's stock decline

Why Portola’s Stock Decline Everybody interested in Portola (PTLA) knows by now that this firm has managed to put two FDA-approved products on the market. They are: Bevyxxa ®  (betrixaban):  The first and only once-daily oral Factor Xa inhibitor, for the prevention...

Read More

October 17, 2018

0

Incyte: A Thoughtful Research and Collaboration Agreement with Abramson Cancer Center

Incyte Announces a Multi-year Research Collaboration with the Abramson Cancer Center at the University of Pennsylvania . The aim of the agreement with Abramson Cancer Center at the University of Pennsylvania as Incyte (INCY) stated in the press release is...

Read More

February 24, 2017

0

Kite Pharma's CAR-T Therapy Passed the Test with High Grades

We keep reiterating that CAR-T cancer immunotherapy was created to stay. More frequent updates about the CAR-T approach further solidified our conviction. Almost every week we are getting news eliminating layer by layer of the true problems about CAR-T therapy...

Read More

March 2, 2017

0

Immunotherapy and some other results from ESMO 2018

IMMUNOTHERAPY   The Checkpoint Inhibitors The most revered news was the discovery of the checkpoint proteins on the surface of the immune system cells. The checkpoint proteins ’ natural job is to put a break on the immune system cells...

Read More

October 24, 2018

0

Why Would a Specific Rheumatoid Arthritis Drug Treat Aggressive Cancers? Read Also: Other Important News

An approved rheumatoid arthritis drug developed and sold by Sanofi could become a new treatment for aggressive cancers. The news came in a Mount Sinai press release announcing that researchers have discovered that a rheumatoid arthritis drug can block a...

Read More

March 3, 2017

0

Ionis Drug Volanesorsen's Reward Outweighs the Mitigated Risk

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals (IONS) , announced positive results from the pivotal Phase 3 APPROACH study of the drug volanesorsen . The results demonstrate that the drug met its primary endpoint of reducing triglyceride levels...

Read More

March 8, 2017

0

Prenatal gene editing has already been performed in laboratory animals

Although the tests are for the prevention of a life-threatening metabolic disorder, the prenatal animal testing may be offering the potential to treat many human congenital diseases before birth. The research, which comes from Children's Hospital of Philadelphia (CHOP) and...

Read More

October 26, 2018

0

Nektar: Killing Pain While Fighting Addiction. Stock is Up 28 Percent

Nektar Therapeutics (NKTR) announced positive results from the SUMMIT-07 Phase 3 efficacy study of its painkiller drug known as NKTR-181 . The drug, which is a first-in-class opioid analgesic is a new chemical entity (NCE). It is the first full...

Read More

March 20, 2017

0

Amgen's Underrated Great News. Array Pharma's Smart Move

AMGEN Amgen’s ( AMGN ) cholesterol lowering drug Repatha is the only drug that has demonstrated protection against heart attack and stroke in high risk patients. Prior to the FOURIER trial, which confirmed the effect of Repatha in lowering cardiovascular...

Read More

March 21, 2017

0

  • Previous
  • 1
  • 2
  • ...
  • 46
  • 47
  • 48
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy